Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

Key Takeaways AbbVie will report Q2 earnings on July 31, with estimates at $15.07 billion for revenues and $2.89 for EPS.Skyrizi and Rinvoq are expected to drive growth, offsetting Humira sales erosion.Neuroscience sales strength contrasts with softness in aesthetics amid Botox and Juvederm slowdown.AbbVie (ABBV) is set to report second-quarter 2025 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $15.07 billion and $2.89 per share, ...